In vitro Diagnostic Multivariate Index Assays (IVDMIA) such as OVA1, ROMA, and OVERA that include multiple biomarkers demonstrate improved clinical performance vs. CA125 alone, indicating that the best diagnostic method for ovarian cancer could entail the combination of multiple biomarkers [41–46]. The gene discussed is MUC16; the disease is ovarian carcinoma.